Kristian Helin is the CEO of The Institute of Cancer Research (ICR) and a professor at the University of London. He has a PhD from University of Copenhagen and was a research fellow at Harvard Medical School. Professor Helin has been a research group leader and Director of research centres in Denmark, Italy, United States and now in the UK. The Helin laboratory has made several seminal discoveries in the field of cell cycle control, epigenetics and cancer. This work has led to the establishment of the biotech companies EpiTherapeutics and Dania Therapeutics.
Dr. Helin has received several prestigious awards for outstanding biomedical research and serves in several editorial boards, committees of advisory boards and grant committees.